Chronic Cough Concerns (AAN)
Price: FREE for members and non-members
Session recorded on November 17, 2022
Speaker: J. Wesley Sublett, MD
Description: The etiology and management of chronic cough is challenging for both patient and provider due to the wide differential and/or multifactorial nature. Understanding the mechanisms that lead to cough is paramount. Cough hypersensitivity syndrome that does not respond to asthma, rhinitis and/or GERD therapy is an emerging area of interest.
Viewers can earn credit by completing the posttest questions.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Primary Care Providers
Fellows-in-Training
Learning Objectives
Upon completion of this activity learners should be able to:
1. Understand the pathogenesis and mechanism of chronic cough
2. Evaluate and treat a patient with chronic cough
3. Explain therapeutic agents in the treatment of cough
All relevant finaicial relationships have been mitigated.
Michael Blaiss, MD, FACAAI Planner
Disclosures: Consultant: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
J. Wesley Sublett, MD, Speaker
Disclosures: Aimmune Independent Contractor; ALK: Independent Contractor; AstraZeneca: Advisor, Speaker, Independent Contractor; BioCryst: Independent Contractor, Researcher; Evidera: Independent Contractor, Researcher; GlaxoSmithKline: Independent Contractor, Researcher; LEO: Independent Contractor, Researcher; Novartis: Independent Contractor, Researcher; Octapharma: Independent Contractor, Researcher; Regeneron: Advisor, Speaker, Independent Contractor, Researcher; Sanofi: Advisor, Speaker, Independent Contractor, Researcher; TEVA: Independent Contractor, Researcher; Byrn Pharma: Advisor; Pfizer: Advisor, Speaker; Optinose: Advisor; Bellus: Advisor
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance